Alnylam Pharmaceuticals's revenue for the
three
months ended in Dec. 2023 was $440 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1,828 Mil.
Alnylam Pharmaceuticals's Revenue per Share for the
three
months ended in Dec. 2023 was $3.50.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $14.35.
During the past 12 months, the average Revenue per Share Growth Rate of Alnylam Pharmaceuticals was 71.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 50.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 75.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 40.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Alnylam Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 112.30% per year. The lowest was -31.50% per year. And the median was 31.90% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alnylam Pharmaceuticals's Revenue
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Revenue falls into.
Alnylam Pharmaceuticals Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,828 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Alnylam Pharmaceuticals Revenue Related Terms
Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Alnylam Pharmaceuticals (Alnylam Pharmaceuticals) Business Description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALNY has been successfully added to your 